Why invest in Hofseth BioCare?

A strong ESG-profile, and patented processes coupled with world class R&D with diversified pipelines including research programs on asthma, COVID-19 and gastro

Ticker: HBC
Last updated: 03.12.2020 13:34
Latest

9.20 NOK

Change

0.10

Change (%)

1.10

OVI 3832 01
LATEST REPORT

Q3 2020 Report

Download our latest report, or view all quarterly and yearly reports in the archives.

16:9
NEXT UP

Financial calendar

Q4 Quarterly report 2020
05.02.2021

Annual Report 2020
19.03.2021

Investor presentation

Download our latest investor presentation in PDF-format for a even deeper insight into our current ongoing business and future potential.

Download presentation

Contact investor relations

James Berger
James Berger
Head of Investor Relations & Strategy
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford Currie
Dr. Crawford Currie
Medical R&D & Investor Relations
+44 7968 195497 cc@hofsethbiocare.no